Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | Arm yourself with 8 influential insights to optimise targeted delivery and blueprint mRNA therapiesSMi's 7th annual conference on RNA Therapeutics will aim to deliver an effective scientific toolkit of ideas to implement targeted delivery and mRNA.
By: SMi Group 1. Sarepta Therapeutics clinical experience with oligonucleotide drugs With the anticipation of two new drugs for the treatment of Duchenne Muscular Dystrophy, soon to be reviewed by the FDA, distinguished scientist Ryszard Kole discusses pre-clinical and clinical experience with oligonucleotide drugs. 2. Rigontec pioneer a novel immuno-oncology treatment approach Rigontec’s proprietary agonists specifically activate RIG-I, inducing both immediate and long-term anti-tumour immunity and have proven substantial local and systemic tumour regression in several relevant in vivo models. CEO and Managing Director, Christian Schetter, will introduce their lead compound with insight into combinatorial approaches to boost immune and tumour response. 3. BioNTech AG development vaccines using mRNA delivery Deputy Vice President for Immunotherapies and Preclinical Research, Mustafa Diken, explains how to optimise mRNA for specific immune response. Vice President for RNA Formulation and Drug Delivery, Hienrich Haas, will also be providing a keynote address offering strategic guidance into formulation and delivery; therapeutic approaches; mRNA stability; and clinical applications. 4. Targeted delivery of antisense oligonucleotide through ligand-conjugate chemistry - Isis Pharmaceuticals explain how! Isis Pharmaceuticals Executive Director, Punit Seth, asks questions such as; What are the characteristics of a successful ligand receptor system for delivering oligonucleotide therapeutics? 5. Curevac revelutionise medicine through natural mRNA CureVac has been successful in optimising the natural structure for RNA-based medicine and Director Nigel Horscroft, will be presenting clinical results on exciting solutions using mRNA technology platforms and vaccine therapeutics. 6. How do MiNa Therapeutics regulate liver transcription with small activating RNA? Delegates will learn how emerging techniques can be applied clinically as Prof. Nagy Habib from Imperial College London exploits oligonucleotides to regulate liver transcription. 7. Gene-specific silencing mechanisms uncovered by Sylentis With a focus on small interfering RNA in targeted eye conditions, R&D Manager, Covadonga Paneda, uncovers gene-silencing mechanisms where small RNA molecules are complimentary to direct protein degradation. 8. Targeting tissues and progressing to clinical studies with Global Acorn CSO Andrew David Miller, asks the question: Are precision therapeutic approaches the answer to enable functional delivery of RNAi effectors beyond the liver? The audience will explore options for more control of RNAi effector PD behaviour in vivo and consider the next steps in clinical application. This is just a snapshot of what will be covered in the agenda for 2016. For further details and a full speaker line-up is available online at: www.therapeutics- RNA Therapeutics 15 – 16 February 2016 Holiday Inn Kensington Forum, London UK http://www.smi- ---END--- About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to- End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|